Αρχική World News FDA Approves Gedatolisib with Fulvestrant, With or Without Palbociclib, for HR-positive, HER2-negative... World News FDA Approves Gedatolisib with Fulvestrant, With or Without Palbociclib, for HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer Από Ogkologos - 9 Σεπτεμβρίου, 2026 168 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study 1 of the VIKTORIA-1 Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ EMA recommends granting a marketing authorisation for daraxonrasib Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? MOST POPULAR How I Rebuilt My Self-Image After a Laryngectomy: A Cancer Survivor’s... 20 Απριλίου, 2023 How Early Cancer Detection and Diagnosis Saved My Life Twice: A... 27 Δεκεμβρίου, 2023 Giving Myself the Most Time and Best Chance at Beating Cancer:... 10 Οκτωβρίου, 2023 Treatment with Tebentafusp Results in Longer Overall Survival Among Previously Untreated... 27 Σεπτεμβρίου, 2021 Φόρτωση περισσοτέρων HOT NEWS Tipifarnib Demonstrates Encouraging Efficacy in Patients with Recurrent and/or Metastatic HNSCC... FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection How Can Occupational Therapy Assist with Chemotherapy-induced Peripheral Neuropathy? Large Study Confirms that HPV Vaccine Prevents Cervical Cancer